Acrivon Therapeutics presents Cowen Health Care Conference data

Acrivon Therapeutics showcases promising data for ACR-368 in serous endometrial cancer at Cowen Health Care Conference

Published on Mar. 2, 2026

Got story updates? Submit your updates here. ›

Acrivon Therapeutics presented data on its investigational drug ACR-368 for the treatment of serous endometrial cancer at the Cowen Health Care Conference. The data showed significant overall response rates in serous endometrial cancer patients with 2 or fewer prior lines of therapy, as well as a favorable safety profile. Acrivon also announced plans to expand the clinical trial to over 20 sites in Europe to further evaluate ACR-368 in this patient population.

Why it matters

Serous endometrial cancer is an aggressive and difficult-to-treat subtype of endometrial cancer, accounting for a disproportionate number of deaths despite representing only a small fraction of total cases. Current treatment options have limited efficacy, highlighting the significant unmet need for new therapies in this patient population. The promising data on ACR-368 presented at the Cowen conference suggests it could potentially address this unmet need.

The details

The data presented at the Cowen conference showed an overall response rate (ORR) of 44% in serous endometrial cancer patients with 2 or fewer prior lines of therapy who received ACR-368 monotherapy. In the broader serous endometrial cancer population with 2 or fewer prior lines, the ORR was 52%. ACR-368 also demonstrated a favorable safety profile, with the most common Grade 3/4 treatment-related adverse events being hematological in nature. To further evaluate ACR-368, Acrivon is expanding the clinical trial to over 20 sites across 4 major European countries.

  • The Cowen Health Care Conference took place on March 2, 2026.
  • Acrivon plans to complete enrollment for the expanded clinical trial in Q4 2026.

The players

Acrivon Therapeutics

A clinical-stage biopharmaceutical company developing precision oncology therapies.

Peter Blume-Jensen, M.D., Ph.D.

Chief Executive Officer, President and Co-Founder of Acrivon Therapeutics.

Mansoor Raza Mirza, M.D.

Chief Medical Officer of Acrivon Therapeutics, former Chief Oncologist at Copenhagen University Hospital and Honorary Congress President of the European Society of Gynecological Oncology (ESGO).

Got photos? Submit your photos here. ›

What they’re saying

“Serous endometrial cancer is characterized by high-grade aplasia and aggressive histological features, and represents a significant unmet need with limited effective treatment options.”

— Mansoor Raza Mirza, Chief Medical Officer, Acrivon Therapeutics (Acrivon Therapeutics)

What’s next

Acrivon plans to complete enrollment for the expanded clinical trial evaluating ACR-368 in serous endometrial cancer patients in Q4 2026.

The takeaway

The promising data on ACR-368 presented at the Cowen Health Care Conference suggests it could potentially address the significant unmet need in serous endometrial cancer, a rare and aggressive subtype of endometrial cancer with limited effective treatment options.